Dataset Information

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

ABSTRACT:

Background

Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001.

Methods

Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0.

Results

The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%-9.5%) in 2008-2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones.

Conclusions

Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.

SUBMITTER: Hofstra LM

PROVIDER: S-EPMC4741360 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra L Marije LM Sauvageot Nicolas N Albert Jan J Alexiev Ivailo I Garcia Federico F Struck Daniel D Van de Vijver David A M C DAMC Åsjö Birgitta B Beshkov Danail D Coughlan Suzie S Descamps Diane D Griskevicius Algirdas A Hamouda Osamah O Horban Andrzej A Van Kasteren Marjo M Kolupajeva Tatjana T Kostrikis Leondios G LG Liitsola Kirsi K Linka Marek M Mor Orna O Nielsen Claus C Otelea Dan D Paraskevis Dimitrios D Paredes Roger R Poljak Mario M Puchhammer-Stöckl Elisabeth E Sönnerborg Anders A Staneková Danica D Stanojevic Maja M Van Laethem Kristel K Zazzi Maurizio M Zidovec Lepej Snjezana S Boucher Charles A B CAB Schmit Jean-Claude JC Wensing Annemarie M J AMJ Puchhammer-Stockl E E Sarcletti M M Schmied B B Geit M M Balluch G G Vandamme A-M AM Vercauteren J J Derdelinckx I I Sasse A A Bogaert M M Ceunen H H De Roo A A De Wit S S Echahidi F F Fransen K K Goffard J-C JC Goubau P P Goudeseune E E Yombi J-C JC Lacor P P Liesnard C C Moutschen M M Pierard D D Rens R R Schrooten Y Y Vaira D D Vandekerckhove L P R LPR Van den Heuvel A A Van Der Gucht B B Van Ranst M M Van Wijngaerden E E Vandercam B B Vekemans M M Verhofstede C C Clumeck N N Van Laethem K K Beshkov D D Alexiev I I Lepej S Zidovec SZ Begovac J J Kostrikis L L Demetriades I I Kousiappa I I Demetriou V V Hezka J J Linka M M Maly M M Machala L L Nielsen C C Jørgensen L B LB Gerstoft J J Mathiesen L L Pedersen C C Nielsen H H Laursen A A Kvinesdal B B Liitsola K K Ristola M M Suni J J Sutinen J J Descamps D D Assoumou L L Castor G G Grude M M Flandre P P Storto A A Hamouda O O Kücherer C C Berg T T Braun P P Poggensee G G Däumer M M Eberle J J Heiken H H Kaiser R R Knechten H H Korn K K Müller H H Neifer S S Schmidt B B Walter H H Gunsenheimer-Bartmeyer B B Harrer T T Paraskevis D D Hatzakis A A Zavitsanou A A Vassilakis A A Lazanas M M Chini M M Lioni A A Sakka V V Kourkounti S S Paparizos V V Antoniadou A A Papadopoulos A A Poulakou G G Katsarolis I I Protopapas K K Chryssos G G Drimis S S Gargalianos P P Xylomenos G G Lourida G G Psichogiou M M Daikos G L GL Sipsas N V NV Kontos A A Gamaletsou M N MN Koratzanis G G Sambatakou H H Mariolis H H Skoutelis A A Papastamopoulos V V Georgiou O O Panagopoulos P P Maltezos E E Coughlan S S De Gascun C C Byrne C C Duffy M M Bergin C C Reidy D D Farrell G G Lambert J J O'Connor E E Rochford A A Low J J Coakely P P O'Dea S S Hall W W Mor O O Levi I I Chemtob D D Grossman Z Z Zazzi M M de Luca A A Balotta C C Riva C C Mussini C C Caramma I I Capetti A A Colombo M C MC Rossi C C Prati F F Tramuto F F Vitale F F Ciccozzi M M Angarano G G Rezza G G Kolupajeva T T Vasins O O Griskevicius A A Lipnickiene V V Schmit J C JC Struck D D Sauvageot N N Hemmer R R Arendt V V Michaux C C Staub T T Sequin-Devaux C C Wensing A M J AMJ Boucher C A B CAB van de Vijver D A M C DAMC van Kessel A A van Bentum P H M PHM Brinkman K K Connell B J BJ van der Ende M E ME Hoepelman I M IM van Kasteren M M Kuipers M M Langebeek N N Richter C C Santegoets R M W J RMWJ Schrijnders-Gudde L L Schuurman R R van de Ven B J M BJM Åsjö B B Kran A-M Bakken AB Ormaasen V V Aavitsland P P Horban A A Stanczak J J JJ Stanczak G P GP Firlag-Burkacka E E Wiercinska-Drapalo A A Jablonowska E E Maolepsza E E Leszczyszyn-Pynka M M Szata W W Camacho R R Palma C C Borges F F Paixão T T Duque V V Araújo F F Otelea D D Paraschiv S S Tudor A M AM Cernat R R Chiriac C C Dumitrescu F F Prisecariu L J LJ Stanojevic M M Jevtovic Dj D Salemovic D D Stanekova D D Habekova M M Chabadová Z Z Drobkova T T Bukovinova P P Shunnar A A Truska P P Poljak M M Lunar M M Babic D D Tomazic J J Vidmar L L Vovko T T Karner P P Garcia F F Paredes R R Monge S S Moreno S S Del Amo J J Asensi V V Sirvent J L JL de Mendoza C C Delgado R R Gutiérrez F F Berenguer J J Garcia-Bujalance S S Stella N N de Los Santos I I Blanco J R JR Dalmau D D Rivero M M Segura F F Elías M J Pérez MJP Alvarez M M Chueca N N Rodríguez-Martín C C Vidal C C Palomares J C JC Viciana I I Viciana P P Cordoba J J Aguilera A A Domingo P P Galindo M J MJ Miralles C C Del Pozo M A MA Ribera E E Iribarren J A JA Ruiz L L de la Torre J J Vidal F F Clotet B B Albert J J Heidarian A A Aperia-Peipke K K Axelsson M M Mild M M Karlsson A A Sönnerborg A A Thalme A A Navér L L Bratt G G Karlsson A A Blaxhult A A Gisslén M M Svennerholm B B Bergbrant I I Björkman P P Säll C C Mellgren Å Å Lindholm A A Kuylenstierna N N Montelius R R Azimi F F Johansson B B Carlsson M M Johansson E E Ljungberg B B Ekvall H H Strand A A Mäkitalo S S Öberg S S Holmblad P P Höfer M M Holmberg H H Josefson P P Ryding U U

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20151129 5

<h4>Background</h4>Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe ...[more]

PMID: 26620652

Similar Datasets

Project description:To investigate the responses to switching to second-line regimens among patients who had received a long-term first-line antiretroviral therapy.Patients switching to second-line regimens from June 2008 to June 2015 were enrolled from an observational cohort. In addition, patients continuing first-line therapy and had a viral load <1000?copies/mL were included as controls in July 2012. All these patients were followed-up for 36 months or until June 2016. The virological, immunological outcomes, and drug resistance were evaluated. Virological failure was defined as viral load ?1000?copies/mL after 6 months of treatment since the start of the study.There were 304 patients switching to second-line regimens and 46 patients remaining on first-line therapy enrolled while having received first-line therapy for a median of 7.6 years. Patients with plasma viral load (VL) ?1000?copies/mL before switching to second-line regimens had a sharp decline in the proportion of virological failure with 26.7%, 20.4%, and 17.0% at 12, 24, and 36 months after regimen switch, respectively (trend test, P?<?.001). Among these patients, individuals with drug resistance (DR) had a better virological responses as compared with those without DR after regimen switching. While patients with VL <1000?copies/mL at inclusion remained a high rate of viral suppression after switching to second-line regimens. So did patients continuing first-line therapy. Among patients with VL ?1000?copies/mL before switching to second-line regimens, the rates of drug resistance were decreased from 79.4% at inclusion to 7.5% at 36 months of regimen switch, with the proportion of NRTI- and NNRTI-related drug resistance from 67.2% and 79.4% to 5.4% and 7.5%, respectively. No PI-related resistance was found. Having self-reported missing doses within a month at follow-ups were independently associated with virological failure at 36 months of switching.HIV-infected patients had viral load ?1000?copies/mL at regimen switch after a long duration of first-line therapy had good virological responses to second-line regimens, especially those harbored drug resistant variants at regimen switch. However, patients with suppressive first-line therapy did not appear to benefit virologically from switching to second-line regimens.

Project description:BackgroundAntiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART.MethodsThe TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene.FindingsWe included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27-1·77 for CD4 cell count <100 cells per μL). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1·48, 95% CI 1·20-1·82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies per mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0·626]).InterpretationWe recorded drug resistance in a high proportion of patients after virological failure on a tenofovir-containing first-line regimen across low-income and middle-income regions. Effective surveillance for transmission of drug resistance is crucial.FundingThe Wellcome Trust.

Dataset Information

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Background

Methods

Results

Conclusions

Publications

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets